About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
N
ASH 2021: Cellular Therapies in Myeloma
By
Yale Cancer Center
FEATURING
Noffar Bar
March 23, 2022
0 Comments
Login to view comments.
Click here to Login
Featured Video
15:50
Seagen
Efficacy and Safety Data of a First Line Treatment Option in Patient…
Feat.
A. Forman
Featured Video
17:12
Seagen
Strategies for Managing Toxicities Associated with a First Line Trea…
Feat.
A. Forman
Related Content
AUTOPLAY
ON
17:59
Parameswaran Hari
Delivering the Best Initial Treatment for Myeloma: Induction Therapy…
09:50
Nina Shah
Maximizing the Initial Gains in Myeloma Therapy: Consolidation and M…
13:27
Shaji Kumar
Evolving Concepts in the Diagnosis and Risk Stratification of Myeloma
15:31
Parameswaran Hari
Refractory and Relapsing Myeloma - When to Treat and Options Availab…
15:11
Ajay Nooka
Early Relapse: Choosing Among Different Second Line Regimens in Myel…
19:41
Peter Voorhees
Approach to the Patient with Refractory & Multiple Relapsed Mult…
18:44
City of Hope
The Promise of Immunotherapy and Newer Agents in Multiple Myeloma
Feat.
A. Krishnan
06:23
Parameswaran Hari
Treating Refractory & Relapsing Myeloma: Current Trends and Reco…
26:57
Saad Usmani
Immune Approaches and Targeted Therapies for Myeloma: The Future
13:30
Helen Heslop
CAR T-cell Therapy for Hematologic Malignancies Other Than CD19
15:10
Krina Patel
Developing CAR T-cells in Multiple Myeloma
03:34
Krina Patel
The Future in Multiple Myeloma: BiTE, CAR T, PI, & IMID
10:38
Krina Patel
How Do We Make Responses Durable in Multiple Myeloma?
11:51
Memorial Sloan Kettering Cancer Center
Aiming for Minimal Residual Disease Negative Status in all Myeloma P…
Feat.
O. Landgren
11:56
Indy Hematology Review
Initial and Maintence Therapy for Multiple Myeloma
Feat.
K. Anderson
05:24
Indy Hematology Review
Therapy for Relapsed Multiple Myeloma
Feat.
K. Anderson
12:32
Indy Hematology Review
What's New in Immunotherapy and Genomics in Multiple Myeloma?
Feat.
K. Anderson
17:47
Dana-Farber Cancer Institute
Relapse Refractory Myeloma and Novel Treatments
Feat.
N. S. Raje
15:02
Krina Patel
Clinical Trials in Myeloma in 2018
16:59
Nina Shah
The Future of CAR T Therapies in Myeloma in 2018
